Revolutionizing Life with Enhanced 3D Printing Technology

Revolutionizing Bioprinting: EU-Funded Researchers Lead Breakthrough in Tissue Engineering

In a groundbreaking development, a team of EU-funded researchers has pioneered a 3D bioprinting technique that enables the growth of living bone, fat, and muscle tissues in a laboratory setting. This innovative approach holds immense promise for a wide array of applications, ranging from leukemia research to the production of cultivated meat.

Nature’s intricate process of constructing with living cells over billions of years has inspired researchers to mimic and accelerate this natural phenomenon. Professor Massimo Vassalli, a leading bioengineering expert at the University of Glasgow, aims to unravel the mysteries of tissue formation and reproduction within lab environments.

Heading the PRISM-LT project, a five-year endeavor supported by the EU until 2027, Vassalli and his team are focused on developing a cutting-edge 3D bioprinting platform for the creation of complex living tissues. These tissues have diverse applications in biomedical research and the emerging field of cultivated meat production.

The core concept driving this project is the creation of Engineered Living Materials (ELMs). These materials, composed partly or wholly of living cells, possess the remarkable ability to grow, adapt, and self-repair in ways that traditional static materials cannot emulate.

Engineered living materials offer dynamic features that conventional materials lack, according to Vassalli, emphasizing the transformative potential of this technology across various industries, from healthcare to food production.

Unlocking the Potential of Engineered Living Materials

The challenge lies in effectively printing living cells into intricate structures without compromising their viability or developmental control. The PRISM-LT team addresses this hurdle by utilizing tiny capsules containing living cells and a gel-like scaffold material referred to as bioink.

By encapsulating living building blocks, the team can precisely position these capsules using a robotic arm or layer them to create sophisticated tissue architectures. This approach diverges from conventional methods that lack biological guidance, ensuring the survival and proper development of the printed cells.

Genetically engineered microbes within the capsules act as biological guides, releasing growth factors to direct stem cells towards desired tissue types during differentiation. The manufacturing process is swift, followed by a maturation period where stem cells evolve into bone, fat, or muscle tissues.

The project’s complexity stems from the need to foster a symbiotic relationship between disparate living components, such as yeast and stem cells, within the same environment. This intricate interaction mirrors the evolutionary processes that have shaped the natural world.

Applications Beyond the Lab

The researchers are focused on recreating specific tissue types, including bone marrow interfaces for biomedical research and muscle-fat structures essential for cultivated meat production. Additionally, the platform will generate miniature tissue models for drug testing and personalized medicine applications.

By engineering various tissues using a unified set of principles, the project aims to cater to diverse needs within the healthcare and food sectors. The team’s efforts in developing 3D bone marrow models hold promise for advancing drug research, particularly in conditions like leukemia.

On the food front, achieving optimal fat distribution in alternative meats is crucial for consumer acceptance. The bioprinting technology employed by the team enables the replication of authentic meat textures, potentially revolutionizing the market.

Despite the exciting prospects, translating this technology into practical applications will take time. While focusing on fundamental principles, the researchers are mindful of future challenges and the need to address consumer perceptions, especially regarding the use of genetically modified microorganisms.

Navigating Regulatory Frontiers

Introducing engineered living materials into mainstream medicine and food production necessitates a paradigm shift in regulatory frameworks. The unique combination of living cells and genetically modified microorganisms in ELMs poses regulatory challenges that current frameworks are ill-equipped to address.

Collaborating with the European Innovation Council, the team is engaging with regulatory bodies like the European Medicines Agency to pave the way for the eventual approval and integration of ELMs into various industries.

While scalability remains a key challenge, the potential impact of ELMs is vast. Vassalli envisions a future where living materials coexist with traditional materials, ushering in a new era of innovation and sustainability.

This article was originally published in Horizon, the EU Research and Innovation Magazine.

Research featured in this article received partial funding from the European Innovation Council (EIC).